Article
A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer
2026-05-29
Abstract excerpt
Androgen receptor (AR)-dependent prostate cancer (PCa) cells require co-activation of ELK1 by AR to activate a critical set of cell cycle and mitosis genes, regardless of hormone - sensitivity. A small molecule antagonist (KCI807) that inhibits AR-dependent growth by selectively binding to AR and blocking its association with ELK1 is limited as a drug by auto-induced metabolism. Using structure-activity data, cons...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- cf175834-9d34-5557-ac42-cb10ec7cae7a
- DOI
- 10.64898/2026.05.26.727474
